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There is a growing realization that tumors are individual, dynamic ecosystems, which consist 10 
of heterogeneous cell populations that differ at the genetic and molecular level, and that this 11 
diversity facilitates their evolutionary 'fitness' and ability to weather selective pressures such 12 
as chemotherapy or radiotherapy1. The genetic heterogeneity of tumors has been known for 13 
decades from cytogenetic studies and, more recently, our understanding has been further 14 
refined by multiple population-based2 studies and a handful of single-cell-sequencing 15 
studies3 across a number of tumors. However, the degree and contribution of other 16 
measures of cellular heterogeneity, such as epigenetic variance, are poorly understood4.  17 
Acute myeloid leukemia (AML) is an aggressive hematological malignancy associated with a 18 
dismal outcome: usually, initial response to therapy is followed by relapse and resistance to 19 
therapy. Both genetic and clinical heterogeneity are evident between patients with AML2, 20 
and genetic heterogeneity within individual leukemias has been demonstrated both at single 21 
time points and longitudinally after relapse5. By contrast, the role of epigenetic variation in 22 
AML is unclear, although several disease characteristics suggest that it might be important. 23 
First, AML is a relatively simple cancer genetically, with only 2–5 driver mutations per patient 24 
coding genome identified by whole-genome sequencing (WGS). In addition, multiple 25 
epigenetic regulators are targeted by mutation, deletion and chromosomal rearrangements 26 
in AML. Finally, altered epigenetic states and patterning, such as DNA methylation and 27 
patterns of histone modifications, are cardinal features of AML6. In this issue of Nature 28 
Medicine, Li et al.7 address the role of epigenetic variation in cancer prognosis, 29 
demonstrating that epigenetic diversity is an important hallmark of AML, and that it seems to 30 
evolve independently of the genetic landscape.  31 
The authors carried out large-scale analysis of epigenomic patterning by using enhanced 32 
reduced representation bisulfite sequencing (ERRBS) to detail DNA methylation in a cohort 33 
of 138 individuals with AML, for whom paired diagnostic and relapse leukemic bone marrow 34 
samples were available. They used the recently described methclone compositional entropy 35 
equation approach8, which analyzes differences in combinatorial methylation patterns in four 36 
adjacent CpG dinucleotides (termed epialleles, Fig. 1) to identify variable regions (eloci) and 37 
which also quantitates the degree of variation or epigenetic allele burden (EPM, eloci per 38 
million loci) at these loci between samples. Samples obtained at diagnosis and at relapse 39 
were compared with normal bone marrow (NBM) and, for each patient pair, with each other. 40 
The methclone technique differs from other measures of methylation heterogeneity (MH), 41 
such as epipolymorphism analysis9, because it measures dynamic changes rather than 42 
capturing a static measure. In addition, whole-exome sequencing (WES) and RNA-seq data 43 
were also available for subsets of patients (WES, n = 48; RNA-seq, n = 19), to enable a 44 
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direct comparison of epigenetic diversity with genetic diversity and transcriptional outcome in 45 
the same individual. 46 
The authors' major finding was that higher epigenetic variance was correlated with a shorter 47 
time to disease relapse when patients were divided into groups on the basis of high and low 48 
EPM, particularly when EPM analysis was limited to promoter eloci. In addition, this 49 
association was independent of other potentially confounding variables, including age and 50 
crude estimates of tumor burden, such as the peripheral white cell count. Importantly, when 51 
the subgroup of patients with available WES data was analyzed similarly, dependent on 52 
mutation burden, no difference was seen in time to relapse between the two groups of high 53 
and low mutation burden. Epigenetic variability was increased in both diagnostic and 54 
relapsed AML, as compared to NBM, but the degree was itself variable upon disease 55 
progression. There was, however, an apparent redistribution of eloci from established 56 
transcriptional regulatory elements, such as CpG islands, promoters and enhancers, at 57 
diagnosis, toward intronic and intergenic regions at relapse. This observation raises the 58 
intriguing possibility that these novel regions might acquire regulatory function with disease 59 
progression. 60 
The authors were then able to cluster the patients into three groups according to 61 
predominance of eloci clusters: unique to diagnosis, unique to relapse or shared between 62 
both relapse and diagnosis. No link was found between these groups and the presence of 63 
specific mutations within these groups; nor was any association found with clonal structure 64 
or complexity. However, individuals with a large number of eloci at diagnosis had fewer 65 
mutations evident at this time point. In addition, individuals with a higher mutational burden 66 
at diagnosis developed substantial numbers of eloci at relapse, which further suggests that 67 
epigenetic and genetic processes have independent trajectories during progression. The 68 
authors further found that gene-expression patterns differed between the clusters, wherein 69 
individuals with high levels of eloci at diagnosis demonstrated an upregulation of genes, 70 
including those encoding signaling proteins, whereas individuals with elevated eloci at 71 
relapse upregulated inflammation and immune-response-related genes. 72 
The authors then focused their studies on longitudinal analysis of an exemplar case at five 73 
separate time points (diagnosis and four subsequent relapses), which further demonstrated 74 
a lack of concordance between genetic and epigenetic variation in the samples at the same 75 
time point. The most substantial increase in epiallele burden was noted at first relapse in this 76 
individual, long before the most striking change in mutational burden, which occurred at third 77 
relapse. This case not only further supported the idea that genetic and epigenetic diversity 78 
may be independent, but also suggests that they may be combinatorial in maintaining the 79 
tumor over the continuum of disease progression. Finally, the authors linked epigenetic 80 
variation to concordant changes in transcription. They found from bulk analysis of all 81 
samples that genes associated with eloci at diagnosis had increased differential expression 82 
between diagnosis and relapse when compared to those without eloci, and that genes 83 
associated with eloci had increased transcriptional heterogeneity in single-cell RNA-seq 84 
analysis. 85 
This study has a number of implications for the role of heterogeneity in tumor biology. The 86 
independence of epigenetic and genetic heterogeneity in AML would be predicted to further 87 
increase clonal diversity and evolutionary fitness, and thus makes evolutionary sense. By 88 
contrast, however, interdependency of genetic and epigenetic events has been shown in 89 
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glioblastoma10, and it will be important to determine any similar relationships in other 90 
malignancies. Furthermore, it is possible that other mediators of the malignant phenotype, 91 
such as altered metabolism, also demonstrate cellular heterogeneity; investigation of this 92 
and any correlation with genetic and epigenetic variation are warranted. In addition, given 93 
that this study focused on individuals who relapse, would the epigenetic heterogeneity of 94 
patients with AML, but with a good prognosis, be less? Additionally, could the EPM measure 95 
at selected eloci be used as a predictive biomarker at disease diagnosis, for instance? 96 
Finally, the mechanism(s) that drive epigenetic variation and the downstream consequences 97 
of this variation are largely unknown and require elucidation. Although the authors' data 98 
suggest that specific mutations—even those in modifiers of DNA methylation such as 99 
DNMT3A, TET2, IDH1 and IDH2—are not correlated with epigenetic variation, they did not 100 
investigate further what actually drives epigenetic diversity. Similarly, the loose correlation 101 
between epiallele burden, specific eloci and alterations in transcription warrants further 102 
investigation, and single-cell analysis is likely to be particularly helpful in determining how 103 
this epigenetic variation alters cellular phenotype. This study therefore paves the way for 104 
further work in larger series of AML samples and in prospective experimental systems to 105 
address these questions.  106 
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Figure Legend 118 
Figure 1. Independence of epigenetic and genetic heterogeneity during the 119 
progression of AML. 120 
Li et al.7 analyzed the genetic and epigenetic heterogeneity of AML at diagnosis and relapse 121 
after treatment; an example here typifies their findings. Differently colored cells represent 122 
genetic diversity and the small open and closed circles, DNA methylation. Their epigenetic 123 
analysis identified strings of four adjacent CpG dinucleotides that were dynamically 124 
methylated during disease progression. At diagnosis, in the six cells shown, there are only 125 
two patterns of combinatorial methylation at the two alleles represented, resulting in low 126 
epigenetic diversity. However, there is a more marked genetic heterogeneity at the same 127 
time point. By contrast, after treatment, there is an increase in epigenetic heterogeneity at 128 
relapse, as demonstrated by the more varied combinatorial methylation pattern, but a 129 
relative decrease in genetic diversity, that is independent of these epigenetic changes.  130 
